These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 7044933)

  • 1. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 2. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
    Schöffling K; Hillebrand I
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
    Hayakawa T; Noda A; Kondo T; Okumura N
    Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G; Karaiskos C; Raptis S
    Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
    Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
    J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Modification of carbohydrate metabolism and oral glucose tolerance test in type II diabetics using the glucosidase inhibitor acarbose].
    Schwartzkopff W; Calder D
    Med Welt; 1984 Feb; 35(6):169-74. PubMed ID: 6369065
    [No Abstract]   [Full Text] [Related]  

  • 7. [Inhibition of intestinal alpha glucosidases in the therapy of diabetes mellitus].
    Fölsch UR; Lembcke B
    Internist (Berl); 1991 Dec; 32(12):699-707. PubMed ID: 1823561
    [No Abstract]   [Full Text] [Related]  

  • 8. [The effect of alpha-glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report].
    Mimura M; Tsukakubo T; Tsujiguchi N; Hoshikawa T
    Masui; 1996 Mar; 45(3):337-9. PubMed ID: 8721135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibitors of alpha-glucosidase].
    Toeller M
    Journ Annu Diabetol Hotel Dieu; 1991; ():203-12. PubMed ID: 1886331
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of acarbose on intestinal disaccharidase: review of its therapeutic potential].
    Sternberg A; Wagner Y; Fireman Z
    Harefuah; 1994 May; 126(9):527-9. PubMed ID: 8034269
    [No Abstract]   [Full Text] [Related]  

  • 11. Alpha-glucosidase inhibitors in diabetes. Introduction.
    Kruseman AC; Sels JP; Wolffenbuttel BH
    Eur J Clin Invest; 1994 Aug; 24 Suppl 3():1. PubMed ID: 8001619
    [No Abstract]   [Full Text] [Related]  

  • 12. [New, in Austria registered specialty drugs. Glucobay (acarbose)].
    Sturm M
    Wien Klin Wochenschr; 1992; 104(11):329-36. PubMed ID: 1621396
    [No Abstract]   [Full Text] [Related]  

  • 13. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
    Clissold SP; Edwards C
    Drugs; 1988 Mar; 35(3):214-43. PubMed ID: 3286212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. alpha-Glucosidase inhibition in the treatment of diabetes mellitus.
    Dimitriadis G; Raptis S
    Horm Metab Res Suppl; 1992; 26():42-9. PubMed ID: 1490691
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term treatment in diabetics with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect on GI hormones.
    Hillebrand I; Aubell R; Boehme K; Bloom SR; Berchtold P
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():683-6. PubMed ID: 6393444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
    Welborn TA
    Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
    [No Abstract]   [Full Text] [Related]  

  • 17. A review of the safety and efficacy of acarbose in diabetes mellitus.
    Yee HS; Fong NT
    Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
    García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
    Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.
    Gérard J; Luyckx AS; Lefebvre PJ
    Diabetologia; 1981 Nov; 21(5):446-51. PubMed ID: 7028558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
    Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
    J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.